| Patent application number | Description | Published |
|---|
| 20080286198 | Novel anti-IGF-IR antibodies and uses thereof - The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers. | 11-20-2008 |
| 20090324600 | Use of an anti-cd151 antibody in the treatment of cancer - The present invention relates to the use of at least one antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and thereby inhibiting tumour growth, in the preparation of a medicament intended for the treatment of cancer. | 12-31-2009 |
| 20100092455 | NOVEL ANTI-PROLIFERATION ANTIBODIES - The present invention relates to novel isolated antibodies, or the derived compounds or functional fragments of same, capable of inhibiting the proliferation of tumor cells in vitro and/or in vivo, said antibodies having been obtained by functional screening. | 04-15-2010 |
| 20100150902 | ANTI-CD151 ANTIBODIES AND THEIR USE IN THE TREATMENT OF CANCER - The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers. | 06-17-2010 |
| 20110165062 | Use of an anti-cd151 antibody for early treatment of cancer - The present invention relates to the use of at least one antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and thereby inhibiting tumour growth, in the preparation of a medicament intended for the early treatment of cancer. | 07-07-2011 |
